Having trouble accessing articles? Reset your cache.

Dulaglutide: Phase III data

Top-line data from the open-label, international Phase III AWARD-4 trial in 884 Type II diabetics showed that once-weekly 1.5 mg subcutaneous

Read the full 216 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE